By Counterforce Health Team in Arikayce (amikacin liposome inhalation) —

How to Get Arikayce Covered by Humana in Washington: Prior Authorization Guide and Appeals Process

Quick Answer: Getting Arikayce Covered by Humana in Washington

Arikayce (amikacin liposome inhalation) requires prior authorization from Humana and is typically approved only for refractory MAC lung disease after 6+ months of failed standard therapy. In Washington, if denied, you have 60 days to request external review through an Independent Review Organization (IRO). First step today: Gather your complete treatment history and culture results, then have your pulmonologist submit the PA request with detailed medical necessity documentation.

Key timelines: Humana PA decisions within 7-14 days, internal appeals within 30-60 days, external review within 20 days (72 hours if expedited).

Table of Contents

  1. When Standard Alternatives Make Sense
  2. Typical MAC Treatment Options on Humana's Formulary
  3. Pros and Cons of Each Approach
  4. Exception Strategy: When to Request Arikayce
  5. Switching Logistics and Provider Coordination
  6. Re-trying for Arikayce Later
  7. Appeals Process in Washington
  8. Required Documentation Checklist
  9. FAQ

When Standard Alternatives Make Sense

Before pursuing Arikayce, most patients with MAC lung disease start with standard combination therapy that's readily covered by Humana. This approach makes clinical sense because 80-90% of patients respond to first-line treatment, and it's required by both medical guidelines and insurance policies before considering more intensive options.

Standard alternatives are appropriate when:

  • You're newly diagnosed with MAC lung disease
  • You haven't completed at least 6 months of guideline-based therapy
  • You can tolerate the standard three-drug regimen
  • Your infection isn't considered severe or rapidly progressive

Contraindications to consider: Some patients can't use standard therapy due to drug interactions (especially rifamycins with certain medications), liver disease, or previous intolerance to macrolides or ethambutol.

Typical MAC Treatment Options on Humana's Formulary

First-Line Triple Therapy (Widely Covered)

Standard regimen includes:

  • Azithromycin 500mg or Clarithromycin 1000mg
  • Ethambutol 25mg/kg (up to 1600mg)
  • Rifampin 600mg or Rifabutin 300mg

These are typically given three times weekly for nodular/bronchiectatic disease or daily for more extensive infection. Humana's formulary generally covers these medications with minimal restrictions.

Alternative Combinations

  • Moxifloxacin: Sometimes substituted for rifampin in cases of intolerance
  • Clofazimine: Emerging as an alternative for refractory cases
  • IV Amikacin: Traditional injectable option for severe disease

Specialty Tier Options

  • Arikayce (amikacin liposome inhalation): Requires prior authorization and documentation of refractory disease
  • Combination products: Some fixed-dose combinations may be available

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for Arikayce Humana PA Lists Humana Provider Portal
6-Month Criterion Must fail standard therapy first Medical necessity letter FDA labeling, ATS/IDSA guidelines
Combination Therapy Cannot be used as monotherapy Treatment plan documentation Clinical policy
Culture Documentation Persistent positive cultures required Lab reports Medical records
Specialist Oversight Pulmonologist or ID physician Provider credentials Treatment notes

Pros and Cons of Each Approach

Standard Triple Therapy

Pros:

  • Readily covered by insurance
  • Extensive safety data
  • Oral administration
  • Lower cost ($200-400/month)

Cons:

  • Multiple drug interactions
  • Requires excellent adherence
  • Regular monitoring needed (vision, liver function)
  • May take 12+ months to see results

Arikayce Add-On Therapy

Pros:

  • FDA-approved for refractory cases
  • Inhaled delivery targets lungs directly
  • Can improve outcomes when standard therapy fails
  • May shorten treatment duration

Cons:

  • Expensive ($45,000+ annually)
  • Requires prior authorization
  • Risk of hearing loss and kidney toxicity
  • Daily nebulizer treatments
  • Must continue background oral therapy

Exception Strategy: When to Request Arikayce

Clinical Criteria That Support Approval

Request Arikayce when you can document:

  1. Confirmed MAC lung disease with positive cultures
  2. At least 6 months of appropriate combination therapy
  3. Persistent culture positivity despite treatment
  4. Specialist management by pulmonology or infectious disease
  5. Appropriate monitoring plan including audiology

Evidence That Strengthens Your Case

  • Serial sputum culture results showing no improvement
  • Documentation of medication adherence and tolerance
  • Evidence of disease progression (imaging, symptoms)
  • Previous successful culture conversion with Arikayce (if restarting)
From our advocates: We've seen the strongest approvals when providers submit a comprehensive timeline showing exactly which medications were tried, for how long, and why each failed. Include pharmacy records if possible—they provide objective proof of adherence that strengthens medical necessity arguments.

Switching Logistics and Provider Coordination

Before Starting the PA Process

Coordinate with your care team:

  • Schedule appointment with pulmonologist or infectious disease specialist
  • Request copies of all culture results from the past 6+ months
  • Gather documentation of current and previous MAC treatments
  • Ensure recent audiometry and kidney function tests are on file

Pharmacy Considerations

  • Specialty pharmacy required: Arikayce must be dispensed through specialty pharmacies
  • Insurance verification: Confirm Humana coverage before shipment
  • Nebulizer equipment: Ensure you have appropriate nebulizer (Lamira Nebulizer System)
  • Storage requirements: Refrigerated storage needed

Timing Your Request

Submit PA requests when:

  • You have complete 6-month treatment documentation
  • Current therapy has clearly failed (persistent positive cultures)
  • You can demonstrate medical necessity
  • Your provider has time for potential peer-to-peer review

Re-trying for Arikayce Later

What to Document During Standard Therapy

Keep detailed records of:

  • Medication names, doses, and duration for each drug tried
  • Culture results with dates and organism identification
  • Side effects or intolerances experienced
  • Imaging results showing disease progression or stability
  • Symptom changes over time

When to Resubmit

Consider resubmitting if:

  • You complete additional months of failed therapy
  • New culture results show persistent infection
  • Disease progression is documented
  • Previous denial was due to incomplete documentation

Strengthening Your Resubmission

  • Include peer-reviewed literature supporting Arikayce use
  • Provide detailed timeline of all treatments attempted
  • Document impact on quality of life and functional status
  • Consider requesting peer-to-peer review upfront

Appeals Process in Washington

Internal Appeals with Humana

Timeline: 30 days for pre-service, 60 days for post-service decisions How to file: Call Humana member services or submit written appeal Required: Copy of denial letter, additional medical records, provider statement

External Review Process

If Humana denies your internal appeal, Washington state law provides strong consumer protections through Independent Review Organizations (IROs).

Key timelines:

  • 60 days to request external review after final Humana denial
  • 20 days for standard IRO decision (72 hours if expedited)
  • 5 business days to submit additional evidence to IRO

How to initiate: Request external review directly through Humana, who must notify the Washington Insurance Commissioner within 3 business days.

IRO decision is binding on Humana and must be honored if coverage is approved.

Washington State Resources

  • Insurance Commissioner Helpline: 1-800-562-6900
  • Appeals guidance: Available at insurance.wa.gov
  • Consumer complaint process: File formal complaints if procedures aren't followed

Step-by-Step: Fastest Path to Approval

Required Documentation Checklist

Before submitting PA request, gather:

✓ Diagnosis confirmation

  • Positive MAC culture reports (species identification)
  • Chest imaging consistent with MAC lung disease
  • Clinical symptoms documentation

✓ Treatment history

  • Complete medication list with dates, doses, duration
  • Pharmacy records showing dispensing history
  • Documentation of adherence and tolerance

✓ Evidence of treatment failure

  • Serial culture results showing persistent positivity
  • Timeline of at least 6 months of appropriate therapy
  • Specialist assessment of treatment response

✓ Medical necessity letter

  • Provider statement explaining why Arikayce is needed
  • Reference to ATS/IDSA guidelines
  • Plan for monitoring and combination therapy

✓ Current status

  • Recent audiometry results
  • Kidney function tests
  • Pulmonary function tests if available

Medical Necessity Letter Checklist

Your provider should include:

  • Patient's MAC diagnosis with ICD-10 codes
  • Detailed history of prior treatments and outcomes
  • Clinical rationale for Arikayce based on published guidelines
  • Planned dosing and administration schedule
  • Monitoring plan for ototoxicity and nephrotoxicity
  • Expected treatment duration and goals

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
"Less than 6 months therapy" Provide complete treatment timeline Pharmacy records, provider notes
"Not refractory disease" Document persistent positive cultures Serial culture results
"Monotherapy planned" Confirm combination regimen Updated treatment plan
"Inadequate monitoring" Establish monitoring protocol Audiology, nephrology referrals
"Not medically necessary" Strengthen clinical justification Peer-reviewed literature, guidelines

When Arikayce Isn't an Option

If Arikayce remains unaffordable or unavailable, discuss these alternatives with your provider:

Other Treatment Intensification Options

  • IV amikacin: Traditional injectable alternative
  • Surgical resection: For localized, refractory disease
  • Combination therapy optimization: Adding clofazimine or other agents

Patient Assistance Options

Counterforce Health specializes in turning insurance denials into successful appeals by creating evidence-backed, payer-specific documentation that addresses denial reasons point-by-point. Their platform helps patients and providers navigate complex prior authorization requirements and appeals processes for specialty medications like Arikayce.

  • Insmed patient assistance: Income-based support programs
  • Foundation grants: Organizations supporting rare disease patients
  • Clinical trials: Investigational combinations or formulations

FAQ

Q: How long does Humana prior authorization take for Arikayce in Washington? A: Standard PA decisions are made within 7-14 days of complete submission. Expedited reviews (for urgent cases) are completed within 72 hours.

Q: What if Arikayce isn't on Humana's formulary? A: You can request a formulary exception by having your provider submit medical necessity documentation explaining why covered alternatives are inappropriate.

Q: Can I request an expedited appeal in Washington? A: Yes, if delay would seriously jeopardize your health. Expedited external reviews must be completed within 72 hours.

Q: Does step therapy apply if I tried standard MAC therapy in another state? A: Documentation from any provider should count, but ensure records clearly show the 6-month treatment requirement was met with appropriate combination therapy.

Q: What's the success rate for Arikayce appeals? A: Success rates vary, but strong clinical documentation showing true refractory disease typically leads to approval, especially through external review processes.

Q: Can I get Arikayce through a clinical trial instead? A: Potentially—check ClinicalTrials.gov for ongoing MAC studies, though most require specific inclusion criteria.

This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan details. For personalized guidance on appeals and coverage options, Counterforce Health provides specialized support for patients navigating insurance denials for specialty medications.

Need help with your appeal? Contact the Washington State Insurance Commissioner at 1-800-562-6900 or visit insurance.wa.gov for consumer assistance and complaint filing.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.